In May 2021 iStopMM reached an important milestone, with the publication of the first results of the screening study in its first article, “Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies” in the Blood Cancer Journal. In this first paper from the iStopMM trial, the methodology and the recruitment phase of the study was described in detail. The paper introduces the study to the scientific community and shows that the particiation rate is high enabling the study to reach its goals.
Prevalence of multiple myeloma precursors revealed for the first time with iStopMM results
March 24, 2023
Researchers at iStopMM have for the first time described the prevalence of smoldering multiple myeloma and the findings indicate that it is present in 0.5%
